
A Rapid, Culture-Free Method to Determine 50% Neutralization Titer (NT50) Using the ACE2-Competitive Bio-Plex Pro SARS-CoV-2 Neutralization Antibody Assay
In this webinar, see how a Bio-Plex Pro Assay could provide a high-throughput culture-free NT50 determination method for current and future SARS-CoV-2 variants.

Measure Neutralizing Antibodies against Any SARS-CoV-2 Variant in 1 Day
Current vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have reduced the severity of the coronavirus disease 2019 (COVID-19). However, the drastic and quick evolution of the virus poses challenges to the development of durable and efficacious therapeutics for vaccine and antibody developers alike. See how the Bio-Plex Pro Human SARS-CoV-2 Neutralization Antibody Custom Assay Developer Kit speeds up the qualitative measurement of neutralizing antibodies (NAbs) against new SARS-CoV-2 variants, removing a roadblock in COVID-19 therapeutic development.

Leading the Way in Our Understanding of COVID-19: Peptide Megapool Assays
Understanding how T cells respond to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical in developing long-term therapeutic approaches, as well as helping inform strategies for future pandemics. Learn how one team at the La Jolla Institute for Immunology in San Diego, California, has been using novel T-cell activation assays to understand how our immune system responds to SARS-CoV-2.

Immune Surveillance in SARS-CoV-2 Vaccine Development
The ability to characterize the target of cell-mediated immune response is crucial during vaccine development. In studying the characterization of SARS-CoV-2 infection pathogenesis in humans, a research team identified neutralizing antibodies that provided context for vaccine antigen design. Discover how the ZE5 Cell Analyzer was used to detect activation-induced markers, measure intracellular cytokines, and identify spike protein–specific antibodies in a rapid, high-throughput manner.

Introducing the Bio-Plex Pro Human IgG SARS-CoV-2 Serology Assays
Meet our newest product supporting the fight against SARS-CoV-2: the Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel. This qualitative multiplex immunoassay kit quickly and efficiently detects IgG antibodies against four SARS-CoV-2 antigens (nucleocapsid, receptor binding domain, spike 1, and spike 2).

Immunological Response Factors to SARS-CoV-2 in Acquired Immunity
Multiple publications report variation in the duration of acquired immunity to SARS-CoV-2. In this webinar, Bio-Rad scientists review these reports and discuss factors that influence longevity of acquired immunity. Learn about the mechanisms behind acquired immunity and how cytokine and chemokine activity, preexisting conditions, and more can affect immunity duration.

Multiplex Immunoassays in the Race for a COVID-19 Vaccine
In vaccine development, safety and efficacy are critical. Recent studies have shown that multiplex immunoassays offer a flexible way to monitor immune responses. With the ever-increasing pressure on scientists to develop a practical COVID-19 vaccine, multiplex immunoassays stand out as a proven tool.

The Role of Aberrant Cytokine Activity in COVID-19 Disease
Presented by: Kenneth Oh, PhD, Collaborations, Applications, and New Technology Senior Global Manager
Kelly King, PhD, Field Application Specialist II
Brad VanderWielen, PhD, Field Application Specialist II
Candice Cox, Global Marketing Manager, Immunoassays
View on demand
Emerging reports from the COVID 19 pandemic include a spectrum of patient symptoms due to the host immune response. In this webinar, Bio-Rad scientists discuss early research and nascent hypotheses about the pathophysiology of SARS CoV 2–induced COVID 19 disease by evaluating cytokine and chemokine profiles, the role of chronic inflammation in comorbidities, and the arc of immune resolution of historical virulent pathogens, such as SARS and MERS.